Fidia Farmaceutici SpA and Akorn, Inc. sign Letter of Intent to develop four ANDA drug products for commercialization.
Fidia strengthens its presence in the North American market.
13/10/2005 - Company news
Fidia Farmaceutici S.p.A. and Akorn Inc. (USA) today announced that they have signed a Letter of Intent, to develop four ANDA drug products.
Click here for more info: PR_Fidia-Akorn.pdf